Schizophrenia: Positive vs Negative Symptoms, Antipsychotics, EPS Management

Schizophrenia: Positive vs Negative Symptoms, Antipsychotics, EPS Management

A practical guide for nurses, clinicians, and students

What Is This?

Schizophrenia is a chronic psychiatric disorder characterized by psychosis (loss of contact with reality) and cognitive dysfunction. This guide breaks down its symptom domains, pharmacological treatment, and management of drug-induced side effects—critical knowledge for frontline care.

Why use this today? - Diagnose accurately: Distinguish between positive (hallucinations, delusions) and negative (apathy, social withdrawal) symptoms to tailor interventions. - Prescribe safely: Choose antipsychotics based on efficacy, side-effect profiles, and patient-specific factors. - Prevent harm: Recognize and manage extrapyramidal symptoms (EPS)—a common and debilitating consequence of antipsychotic use.

Why It Matters

Schizophrenia affects 1% of the global population, with suicide rates 5–10x higher than the general public. Misdiagnosis or poor medication management leads to: - Hospital readmissions (costing healthcare systems billions annually). - Functional decline (unemployment, homelessness, social isolation). - Medication non-adherence (due to side effects like EPS or metabolic syndrome).

Real-world impact: - Nurses must monitor for early signs of EPS (e.g., muscle rigidity, tremors) to prevent permanent movement disorders. - Clinicians must balance symptom control with quality of life (e.g., avoiding weight gain from second-generation antipsychotics). - Patients/families need clear education on symptom triggers (e.g., stress, substance use) and medication adherence.

Core Concepts

1. Positive vs. Negative Symptoms

Schizophrenia symptoms are classified into three domains, but positive and negative are the most clinically actionable.

Key takeaway: - Positive symptoms respond well to antipsychotics. - Negative symptoms are harder to treat and often persist, contributing to long-term disability.

2. Antipsychotics: First vs. Second Generation

Antipsychotics are the cornerstone of schizophrenia treatment. They primarily block dopamine D2 receptors, but differ in side-effect profiles and efficacy.

Critical notes: - Clozapine is the most effective antipsychotic but requires weekly blood monitoring (risk of agranulocytosis). - Aripiprazole is a partial D2 agonist, making it unique (lower EPS/metabolic risk but may worsen akathisia). - Long-acting injectables (LAIs) (e.g., haloperidol decanoate, risperidone microspheres) improve adherence in non-compliant patients.

3. Extrapyramidal Symptoms (EPS): Recognition & Management

EPS are movement disorders caused by dopamine blockade in the nigrostriatal pathway. They are dose-dependent and more common with first-generation antipsychotics.

Types of EPS

Red flags for TD: - Orofacial movements (e.g., grimacing, tongue thrusting). - Worsens with stress, improves with sleep. - Often unnoticed by the patient (ask family members).

Prevention is key: - Use lowest effective dose of antipsychotics. - Avoid anticholinergics unless treating acute EPS (they worsen TD). - Monitor with AIMS (Abnormal Involuntary Movement Scale) every 3–6 months.

How It Works: The Dopamine Hypothesis

Schizophrenia is linked to dopamine dysregulation in four key pathways:

Key insight: - First-gen antipsychotics block D2 globally-high EPS risk. - Second-gen antipsychotics block D2 + 5-HT2A-lower EPS risk (serotonin modulates dopamine release).

Hands-On: Step-by-Step Management

1. Assessing a Patient with Schizophrenia

Prerequisites: - Basic psychiatric assessment skills. - Access to AIMS scale (for TD monitoring). - Knowledge of antipsychotic side effects.

Step-by-step:
1. Screen for positive symptoms: - "Do you hear voices when no one is around?" - "Do you feel like people are plotting against you?"
2. Screen for negative symptoms: - "Do you feel motivated to do things you used to enjoy?" - "Do you find it hard to express emotions?"
3. Assess for EPS: - Dystonia: "Do you have muscle spasms or stiffness?" - Akathisia: "Do you feel restless or unable to sit still?" - Parkinsonism: Check for tremor, rigidity, bradykinesia. - TD: Observe for involuntary movements (ask patient to stick out tongue, tap fingers).
4. Review medication history: - Current antipsychotic, dose, duration. - Previous trials (response, side effects).
5. Check for metabolic side effects: - Weight, waist circumference, blood pressure, fasting glucose, lipids.

Expected outcome: - Clear symptom profile (positive > negative > cognitive). - Side-effect burden (EPS, metabolic, sedation). - Treatment plan (adjust dose, switch med, add adjunct).

2. Switching Antipsychotics (Example: Haloperidol-Risperidone)

When to switch: - Poor response to current med. - Intolerable side effects (e.g., EPS, weight gain).

Step-by-step:
1. Choose new antipsychotic: - Risperidone (good balance of efficacy/side effects). - Aripiprazole (if metabolic concerns). - Clozapine (if treatment-resistant).
2. Cross-taper over 2–4 weeks: plaintext Week 1: Haloperidol 5 mg-Risperidone 1 mg Week 2: Haloperidol 2.5 mg-Risperidone 2 mg Week 3: Haloperidol 0 mg-Risperidone 3 mg
3. Monitor for: - Withdrawal dyskinesia (rebound EPS if stopping haloperidol too fast). - New side effects (e.g., risperidone-hyperprolactinemia).
4. Adjust dose based on response: - Risperidone target: 2–6 mg/day. - Aripiprazole target: 10–30 mg/day.

Expected outcome: - Reduced EPS (if switching from first-gen). - Improved tolerability (e.g., less weight gain with aripiprazole). - Stable or improved symptom control.

3. Managing Acute EPS (Example: Dystonia)

Scenario: Patient on haloperidol 10 mg/day develops oculogyric crisis (eyes locked upward).

Step-by-step:
1. Recognize the emergency: - Painful, sustained muscle contraction. - Risk of laryngeal dystonia (airway obstruction).
2. Administer anticholinergic: - Benztropine 2 mg IM/IV (onset: 15–30 min). - Diphenhydramine 50 mg IM/IV (alternative).
3. Monitor response: - Symptoms should resolve within 30–60 min. - If no improvement, repeat dose in 30 min.
4. Prevent recurrence: - Reduce haloperidol dose or switch to atypical. - Add oral benztropine 1–2 mg BID for 1–2 weeks.

Expected outcome: - Rapid resolution of dystonia. - Prevention of future episodes (dose adjustment, switch med).

Common Pitfalls & Mistakes

Best Practices

For Symptom Management

Target positive symptoms first (they respond best to antipsychotics). ? Address negative symptoms early (social skills training, CBT, adjunct meds like antidepressants). ? Use LAIs for non-adherent patients (e.g., risperidone microspheres, paliperidone palmitate).

For Side-Effect Prevention

Start low, go slow (e.g., risperidone 1 mg-titrate to 2–4 mg). ? Monitor metabolic parameters (weight, glucose, lipids) every 3 months. ? Avoid anticholinergics unless treating acute EPS (they worsen TD and cognition).

For Patient Education

Teach about EPS signs (e.g., "If your tongue feels stiff or you can’t sit still, tell us immediately"). ? Explain metabolic risks (e.g., "Olanzapine may cause weight gain—let’s check your blood sugar"). ? Involve families (they often notice negative symptoms or TD before the patient).

Tools & Frameworks